ASK REDCHAT ANYTHING ABOUT ARBUTUS BIOPHARMA CORPORATION
Arbutus Biopharma Corporation (NASDAQ: ABUS)
Listen to this Section
$4.48
+0.0650
(
+1.47% )
1.7M
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Imdusiran +NA therapy +VTP-300DetailsHepatitis B |
Phase 2a |
| Imdusiran +NA therapy +IFNDetailsHepatitis B |
Phase 2a |
| AB-101DetailsHepatitis B |
Phase 1 |
| AB-836 (capsid inhibitor)DetailsHepatitis B |
Failed |
| Imdusiran + NA therapy + low dose durvalumabDetailsHepatitis B |
Failed |
| AB-161 (Oral RNA destabilizer)DetailsHepatitis B |
Failed |
Market Data
|
| Open |
$4.48 |
| Previous Close |
$4.41 |
| Volume |
1.7M |
| Market Cap |
$881.02M |
| Day Range |
$4.30 - $4.63 |
| 52 Week Range |
$3.04 - $5.10 |
| Shares Outstanding |
197.54M |
| Change % |
+1.47% |
| Net Change |
▲ 0.0650 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2007 |
| Country | United States |
Insider Ownership Transactions
Total Amount Purchased:
-943,900.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-05 |
Sale |
-123800.00 |
McElhaugh Michael J. |